利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.034 秒)

    Heterocyclic ppar modulators
    1.
    发明申请
    Heterocyclic ppar modulators 审中-公开
    杂环ppar调节剂

    公开(公告)号：US20060241157A1

    公开(公告)日：2006-10-26

    申请号：US10540341

    申请日：2003-12-31

    申请人： Scott Conner ,  Tianwei Ma ,  Nathan Mantlo ,  Daniel Mayhugh ,  Jeffrey Schkeryantz ,  Alan Warshawsky ,  Guoxin Zhu

    发明人： Scott Conner ,  Tianwei Ma ,  Nathan Mantlo ,  Daniel Mayhugh ,  Jeffrey Schkeryantz ,  Alan Warshawsky ,  Guoxin Zhu

    IPC分类号： A61K31/425 ,  A61K31/42 ,  A61K31/415 ,  C07D261/02 ,  C07D231/12

    CPC分类号： C07D231/12 ,  C07D233/20 ,  C07D233/22 ,  C07D233/64 ,  C07D249/06 ,  C07D253/04 ,  C07D261/08

    摘要： The present invention is directed to compounds represented by the following structural formula, Formula I: wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) E is C(R3)(R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; (e) Z1 and Z2 are each independently selected from the group consisting of N, O, and C with the proviso that at least one of Z1 and Z2 is N; (f) Z3 is selected from the group consisting of N, O, and C. (g) R8 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C4 alkylenyl and halo; (h) R9 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkylenyl, halo, aryl-C0-C4 alkyl, heteroaryl, C1-C6 allyl, and OR29.

    摘要翻译： 本发明涉及由以下结构式（I）表示的化合物：其中：（a）X选自单键，O，S，S（O）2和N; （b）U是脂族连接体; （c）Y选自O，C，S，NH和单键; （d）E是C（R3）（R4）A或A，其中（i）A选自羧基，四唑，C 1 -C 6烷基腈，甲酰胺，磺酰胺和酰基磺酰胺; （e）Z1和Z2各自独立地选自N，O和C，条件是Z1和Z2中的至少一个是N; （f）Z 3选自N，O和C.（g）R 8选自氢，C 1 -C 6烷基，C 1 -C 4亚烷基和卤素; （h）R 9选自氢，C 1 -C 4烷基，C 1 -C 4亚烷基，卤素，芳基-C 0 -C 4烷基，杂芳基，C 1 -C 6烯丙基和OR 29。

    Triazole ppar modulators
    2.
    发明申请
    Triazole ppar modulators 失效
    三唑ppar调节剂

    公开(公告)号：US20070112045A1

    公开(公告)日：2007-05-17

    申请号：US10580202

    申请日：2004-12-21

    申请人： Nathan Mantlo ,  Antonio Navarro ,  Ashraf Saeed ,  Douglas Gernert ,  Tianwei Ma ,  Lance Pfeifer

    发明人： Nathan Mantlo ,  Antonio Navarro ,  Ashraf Saeed ,  Douglas Gernert ,  Tianwei Ma ,  Lance Pfeifer

    IPC分类号： A61K31/433 ,  A61K31/4245 ,  A61K31/4196 ,  C07D285/12 ,  C07D271/10 ,  C07D249/08

    CPC分类号： A61K31/4196 ,  A61K31/4245 ,  A61K31/433 ,  C07D249/08 ,  C07D271/107 ,  C07D285/12

    摘要： The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) W is N, O or S; (e) E is C(R3)(R4)A or A and wherein; (f) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsufonamide. The other substituents are defined in the claims; the compounds are modulators of peroxisome proleferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders.

    摘要翻译： 本发明涉及由下列结构式（I）表示的化合物：其中：（a）X选自单键，O，S，S（O）2， SUB>和N; （b）U是脂族连接体; （c）Y选自O，C，S，NH和单键; （d）W是N，O或S; （e）E是C（R3）（R4）A或A，其中; （f）A选自羧基，四唑，C 1 -C 6烷基腈，甲酰胺，磺酰胺和酰基磺酰胺。 其它取代基在权利要求书中定义; 该化合物是过氧化物酶体促进剂激活受体（PPAR）的调节剂，可用于治疗糖尿病和其他代谢紊乱。

    PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS
    4.
    发明申请
    PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS 审中-公开
    过氧化物促进剂激活受体调节剂

    公开(公告)号：US20100099725A1

    公开(公告)日：2010-04-22

    申请号：US12522723

    申请日：2008-02-12

    申请人： Lance Allen Pfeifer ,  Tianwei Ma ,  Nathan Bryan Mantlo ,  Laura Frey Michael ,  Fese Mambo Mokube ,  Chahrzad Montrose-Rafizadeh

    发明人： Lance Allen Pfeifer ,  Tianwei Ma ,  Nathan Bryan Mantlo ,  Laura Frey Michael ,  Fese Mambo Mokube ,  Chahrzad Montrose-Rafizadeh

    IPC分类号： A61K31/4196 ,  C07D249/12 ,  A61P9/10

    CPC分类号： C07D401/06 ,  C07D249/12

    摘要： The present invention is directed to compounds of the structural Formula: wherein: R1 is H or —C1-C3 alkyl; R2 is selected from the group consisting of —H, —C1-C4 alkyl, —C1-C3 alkyl-CF3, phenyl, and pyridinyl; and R3 is selected from the group consisting of —H, —C1-C4 alkyl, —C1-C3 alkyl-O—CH3, —CH2-cyclopropyl, CH2—C═CH2, —CH2CH2-(2-F-phenyl), and phenyl substituted with from 1 to 2 fluorines; provided that when R1 and R2 are each H, then R3 is selected from the group consisting of —C1-C4 alkyl, —C1-C3 alkyl-O—CH3, —CH2-cyclopropyl, —CH2—C═CH2, —CH2CH2-(2-F-phenyl), and phenyl substituted with from 1 to 2 fluorines; or stereoisomers and pharmaceutically acceptable salts thereof.

    摘要翻译： 本发明涉及结构式的化合物：其中：R 1是H或-C 1 -C 3烷基; R 2选自-H，-C 1 -C 4烷基，-C 1 -C 3烷基-CF 3，苯基和吡啶基; 并且R 3选自-H，-C 1 -C 4烷基，-C 1 -C 3烷基-O-CH 3，-CH 2 - 环丙基，CH 2-C≡CH2，-CH 2 CH 2 - （2-F-苯基）， 和被1至2个氟取代的苯基; 条件是当R 1和R 2各自为H时，R 3选自-C 1 -C 4烷基，-C 1 -C 3烷基-O-CH 3，-CH 2 - 环丙基，-CH 2-C≡CH2，-CH 2 CH 2 - （2-F-苯基）和被1至2个氟取代的苯基; 或立体异构体及其药学上可接受的盐。